Publicacións en colaboración con investigadores/as de University of Bari Aldo Moro (77)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Agreement between local and central anti-synthetase antibodies detection: results from the Classification Criteria of Anti-Synthetase Syndrome project biobank

    Clinical and experimental rheumatology, Vol. 42, Núm. 2, pp. 277-287

  3. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

  4. Elevated Troponins after COVID-19 Hospitalization and Long-Term COVID-19 Symptoms: Incidence, Prognosis, and Clinical Outcomes—Results from a Multi-Center International Prospective Registry (HOPE-2)

    Journal of Clinical Medicine, Vol. 13, Núm. 9

  5. N-Adamantyl-1-alkyl-4-oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as Fluorescent Probes to Detect Microglia Activation through the Imaging of Cannabinoid Receptor Subtype 2 (CB2R)

    Journal of Medicinal Chemistry, Vol. 67, Núm. 13, pp. 11003-11023

  6. Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studies

    Joint Bone Spine, Vol. 91, Núm. 2

  7. Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care

    The Journal of rheumatology, Vol. 51, Núm. 4, pp. 378-389

2023

  1. Development of N-(1-Adamantyl)benzamides as Novel Anti-Inflammatory Multitarget Agents Acting as Dual Modulators of the Cannabinoid CB2 Receptor and Fatty Acid Amide Hydrolase

    Journal of Medicinal Chemistry, Vol. 66, Núm. 1, pp. 235-250

  2. Diminishing benefits of urban living for children and adolescents’ growth and development

    Nature, Vol. 615, Núm. 7954, pp. 874-883

  3. ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 16, pp. 3037-3050

  4. Fluorescence based HTS-compatible ligand binding assays for dopamine D3 receptors in baculovirus preparations and live cells

    Frontiers in Molecular Biosciences, Vol. 10

  5. Global variation in diabetes diagnosis and prevalence based on fasting glucose and hemoglobin A1c

    Nature Medicine, Vol. 29, Núm. 11, pp. 2885-2901

  6. N-adamantyl-anthranil amide derivatives: New selective ligands for the cannabinoid receptor subtype 2 (CB2R)

    European Journal of Medicinal Chemistry, Vol. 248

  7. One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment

    Journal of Rheumatology, Vol. 50, Núm. 8, pp. 1009-1019

  8. Post-COVID-19 Symptoms and Heart Disease: Incidence, Prognostic Factors, Outcomes and Vaccination: Results from a Multi-Center International Prospective Registry (HOPE 2)

    Journal of Clinical Medicine, Vol. 12, Núm. 2

  9. Quantitative titanium imaging in fish tissues exposed to titanium dioxide nanoparticles by laser ablation-inductively coupled plasma-mass spectrometry

    Microchimica Acta, Vol. 190, Núm. 8

2022

  1. After JAK inhibitor failure: To cycle or to switch, that is the question - Data from the JAK-pot collaboration of registries

    Annals of the Rheumatic Diseases, Vol. 82, Núm. 2, pp. 175-181

  2. Design, Synthesis and 5-HT1A Binding Affinity of N-(3-(4-(2-Methoxyphenyl)piperazin-1-yl)propyl)tricyclo[3.3.1.13,7 ]decan-1-amine and N-(3-(4-(2-Methoxyphenyl) piperazin-1-yl)propyl)-3,5-dimethyl-tricylo[3.3.1.13,7 ]decan-1-amine

    MolBank, Vol. 2022, Núm. 1

  3. Dose-response assessment of cerebral P-glycoprotein inhibition in vivo with [18F]MC225 and PET

    Journal of Controlled Release, Vol. 347, pp. 500-507

  4. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration

    Annals of the Rheumatic Diseases, Vol. 81, Núm. 10, pp. 1358-1366